Howard Greene

Howard Greene serves as the Chairman at Satiogen. He has provided strategic advice and funding for Satiogen, is named on several patent applications, and serves as Chairman. Prior to his retirement in 1998, he was Chairman of Amylin Pharmaceuticals, Inc., a company he co-founded in 1987 to pioneer research of the hormone amylin, which was discovered in the same year. He holds several patents directed to using the hormone amylin in diabetes therapy. Before starting Amylin, he co-founded Biovest Partners, a venture capital firm that in two years provided seed capital and management leadership for six medical technology start-up companies, including Amylin, all of which went public. Prior to Biovest, Ted was CEO of Hybritech Incorporated, essentially from inception until its acquisition by Eli Lilly and Company in 1986. At Hybritech he was co-inventor of its principal product line, a monoclonal antibody assay system that has led to a new generation of immunodiagnostics, including the PSA screening test for prostate cancer. Before Hybritech, he was an executive with Baxter Healthcare Corporation, and prior to that he was a consultant with McKinsey & Company. He is presently a director of several early stage startups in the biotech and internet fields. He holds a BA in physics from Amherst College and an MBA from Harvard University.